|Bid||53.87 x 1800|
|Ask||53.98 x 4000|
|Day's Range||51.13 - 52.70|
|52 Week Range||38.48 - 61.71|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||15.40|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||1.60 (3.21%)|
|Ex-Dividend Date||May 12, 2022|
|1y Target Est||59.33|
Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time "is not a crowd-pleaser," Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen.
In this article, we discuss the top 10 value stocks hedge funds are buying in 2022. If you want to see more of the value stocks that elite investors are favoring, click Top 5 Value Stocks Hedge Funds are Buying in 2022. As the Federal Reserve signals further monetary tightening, hedge funds and retail investors […]
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.